Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468788 | 0.80 | HSD17B3 (0.42) | MEN1KMT2AMAPTALDH1A1ATM | |
| Aspartic Acid SCHEMBL3415384 | 0.80 | GRIK1 (0.35) | — | |
| SCHEMBL8909319 | 0.79 | — | — | |
| SCHEMBL27677726 | 0.78 | HSD17B3 (0.44) | MEN1KMT2ATSHRMAPTALDH1A1 | |
| SCHEMBL27524908 | 0.78 | HSD17B3 (0.44) | MEN1KMT2ATSHRMAPTALDH1A1 | |
| SCHEMBL28229004 | 0.76 | KMT2A (0.31) | KMT2A | |
| SCHEMBL2027730 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2ASMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL28616609 | 0.73 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL347103 | 0.73 | LDHA (0.32) | SMN1; SMN2 | |
| SCHEMBL6022461 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| CN-111569086-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-111558049-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4212181-A2 | METHYLENE CARBAMATE LINKERS FOR USE WITH TARGETED-DRUG CONJUGATES | Seagen Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230033133-A1 | VACCINE CONJUGATES | ULTIMOVACS AB (SE) | 2023-02-02 | — | — | US | disclosed |
| EP-4069283-A1 | VACCINE CONJUGATES | Ultimovacs AB (SE) | 2022-10-12 | — | — | EP | disclosed |
| CN-114901305-A | Vaccine conjugates | 乌尔蒂莫瓦科斯公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220054650-A1 | Methylene Carbamate Linkers for use with Targeted-Drug Conjugates | SEATTLE GENETICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11116847-B2 | Methylene carbamate linkers for use with targeted-drug conjugates | SEAGEN INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2015095755-A1 | METHYLENE CARBAMATE LINKERS FOR USE WITH TARGETED-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20100297025-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET. | 2010-11-25 | — | — | US | disclosed |
| US-7780953-B2 | Compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET (FR) | 2010-08-24 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-20040253181-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | GUERBET (FR) | 2004-12-16 | — | — | US | disclosed |
| WO-2001027628-A1 | ANTIBIOTIC-METAL COMPLEXES IN THE DETECTION OF GRAM-NEGATIVE BACTERIA AND OTHER BIOLOGICAL ANALYTES | OLSTEIN ALAN D (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | CASP3 3642/4885MEN1 4508/4885CYP3A4 576/4885 |
| US-20100297025-A1 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives | PHOSPHO1, SGMS2, PTEN | CASP3 4055/4885MEN1 295/4885CYP3A4 4356/4885 |
| US-11116847-B2 | Methylene carbamate linkers for use with targeted-drug conjugates | MCL1, BID, MTDH | CASP3 6/4885MEN1 267/4885CYP3A4 1838/4885 |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | MSN, AURKA, AURKC | CASP3 460/4885MEN1 948/4885CYP3A4 3276/4885 |
| US-20230033133-A1 | VACCINE CONJUGATES | KLK3, CD4, CD74 | CASP3 1395/4885MEN1 826/4885CYP3A4 4848/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | CASP3 460/4885MEN1 948/4885CYP3A4 3276/4885 |
| US-20220054650-A1 | Methylene Carbamate Linkers for use with Targeted-Drug Conjugates | MCL1, BID, MTDH | CASP3 6/4885MEN1 267/4885CYP3A4 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.